LifeVantage: A New CEO, A New Fiscal Calendar, and a Missing Forecast
Revenue fell 22%, guidance disappeared, and a $58.5 million buyback sits unused against a $66 million market cap
LFVN · Earnings Call · 2026-11-09
Ninety days in, the numbers got worse and the forecast vanished
Terrence Moorehead has run LifeVantage for just over a quarter, and his first earnings call as CEO was candid about the starting point. Net revenue fell 22% to $37.1 million in the September quarter and adjusted EBITDA came in at $1.9 million, or 5.2% of revenue versus 8.2% a year earlier. “The decrease was primarily driven by continued downward pressure in the number of orders from our active consumer base and lower average order size” — Carl A. Aure, Chief Financial Officer · 2026-11-09 — a formulation that has become a refrain, with average order size now a fixture of this company's keyword profile after its earlier spike.
What makes the quarter notable is not the decline itself but the removal of the scaffolding around it. In August, CFO Carl Aure was still sketching a second-half arc: “When we get to our fiscal Q3 into Q4, that's really where we anticipate that we hopefully can turn the trend line and really start to see a little bit of momentum associated with those strategies that we're working on” — Carl Aure, Chief Financial Officer · 2026-08-27. A quarter later the turn has not arrived, and the company has stopped putting numbers on anything.
That work is progressing, so I am not gonna get ahead of it, and we are not providing formal guidance today.
The stated reasons — a new CEO and a change of fiscal year to the calendar year starting January 1, 2027 — are legitimate but convenient. The fiscal-year change, announced as a simplification for "strategy, planning, budgeting, incentives, innovation, commercial activation," also dissolves the awkward comparison-management exercise the CFO had been running for two quarters. Note that formal guidance was itself a top-five company keyword last quarter; it has now migrated from promise to excuse.
The hero product stopped being the hero
In late 2024, GLP 1 was the single most prominent keyword in this company's vocabulary, attached to the MindBody launch with enormous momentum. Then-CEO Steve Fife explained the trap two quarters ago: “Over the last year, MINDBODY became the enrollment story for many of our consultants... but we lost some momentum around the other hero products that we have” — Steve Fife, President and Chief Executive Officer · 2026-02-04. That proved less a speed bump than a broken engine. This quarter MindBody is cited as a drag — "lower sales from our MindBody GLP-1 System" — and, more damagingly, as a gross-margin problem, with an inventory charge against a product that was once supply-constrained. Gross margin fell to 75.4% from 79.5%, with the company claiming 78.2% excluding the MindBody inventory allowance.
The contrast with the broader market is the point. GLP-1 remains one of the most durable consumer themes in the global tape — GLP 1 growth still shows up among 90-day advancers, WW is running a GLP-1 success program, and Hims is building a weight-loss assortment. The wave is real and still moving; LifeVantage's natural-alternative vehicle simply stopped riding it. That is a company problem dressed as a category problem.
The LoveBiome acquisition, bought in October 2025 for $3.7 million cash plus an earn-out, no longer gets to be a growth story either — it is now merely an offset, with the company acknowledging that "these declines were partially offset by sales of the LoveBiome product line." A full quarter of acquired revenue and revenue is still down 22%.
A new story, and it is 12 to 18 months out
The genuinely new material on this call is rhetorical: a repositioning around biology rather than ingredients. Moorehead argues LifeVantage can occupy "white space" as the next generation of health and science, launching a campaign built on research showing the lead Protandim product “activates the body's natural defense system to protect the body from environmental toxins like microplastics, pesticides, pollution” — Terrence O. Moorehead, President and Chief Executive Officer · 2026-11-09. Keywords like body from environmental toxins and new campaign are fresh vocabulary for this company — nowhere in twelve quarters of keyword history does microplastics or cellular imagery appear. Before-and-after cell images are a real strategic departure from the "activation" language this company has used for years.
But the execution calendar is slow and back-end loaded. A new North American website and digital platform in the second calendar quarter of 2027; a seller business suite in the third quarter of 2027; AI coaching and decision tools “kind of 12 to 18 months out” — Terrence O. Moorehead, President and Chief Executive Officer · 2026-11-09. That is the same website upgrade program the CEO described in August as "a fairly major kind of program" — the theme is not new, only the dates. Capital spending is running about $1 million a quarter against $3 to $3.5 million annualized, so the transformation is being funded from a very small base. The stated plan is to fund it from SG&A cuts, with Moorehead conceding only that "we realize we need to reset the economics of the business." No number, no timeline, no quantum.
What is missing matters too. Canada, international penetration, gut health, the HealthEdge stack, and the consultant-recruitment machinery that once dominated these calls barely register this quarter. International is down 21.2% and gets a paragraph. The one recurring claim that survives — improving retention metrics for consultants and customers, now several quarters running — is offered without numbers.
Cash, a dividend, and an unused buyback
What keeps this from being a distress story is the balance sheet. $13.7 million of cash, no debt, a $5 million undrawn revolver, and $500,000 of positive operating cash flow in the quarter. Effective net cash stands around $22 million with no borrowing against it, and liabilities are just 46% of assets. At $37 million a quarter, that is real runway.
Which makes the capital allocation curious. Carl Aure noted: “We did not repurchase any shares during the quarter, and $58.5 million remains under our $60 million share repurchase authorization.” — Carl A. Aure, Chief Financial Officer · 2026-11-09 Against a market capitalization of roughly $66 million, that authorization covers nearly 90% of the equity — and yet nothing was bought, despite shares trading at 0.3x revenue, down about two-thirds year over year. Six months ago the same CFO was “still very committed to the share buyback... looking to opportunistically buy over the next few quarters as market conditions permit” — Carl Aure, Chief Financial Officer · 2026-05-06. In fairness, the company is paying a $0.05 quarterly cash dividend and hoarding for a rebuild; but a buyback authorized at near the entire float that goes unused while the stock sits 22.7% below its August peak of $6.84 reads as capital discipline without conviction.
The tape has noticed. The shares are down 15.8% over the last 90 trading days in a nearly straight decline, and the valuation arithmetic has become strange: 8.2x operating income but 363x free cash flow less stock-based comp — a reminder of how small the earnings base has become. Latest reported fundamentals, through the June quarter, still show $44 million in quarterly revenue; the just-reported September quarter is $37.1 million.
The bottom line: LifeVantage has a new chief executive, a credible diagnosis, a differentiated-sounding product story, and a fortress-lite balance sheet. It also has a shrinking core product, no guidance, no cost number, and a transformation whose first deliverables land in mid-2027. The market is being asked to underwrite a rebrand on faith. The next real test is not the next earnings call — it is whether the second-calendar-quarter 2027 website launch actually arrives, and whether the company can quantify anything before then.